As part of a special issue entitled: [Clinical Applications of Metronomic Chemotherapy in the Journal of Clinical Medicine , Banchi M, Fini E, Crucitta S, Bocci G from the Department of Clinical and Experimental Medicine, University of Pisa, VItaly have just published a review article : Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies. The full text is freely available here.

Abstract

Metronomic chemotherapy (MC) is the frequent, regular administration of drug doses designed to maintain a low, but active, range of concentrations of chemotherapeutic drugs, during prolonged periods of time without inducing excessive toxicities. To date, more than 400,000 children and adolescents under the age of 20 are diagnosed with cancer, per year, with 80% survival in most high-income countries, but less than 30% in low- and middle-income ones. In this review, we summarized the principal preclinical and clinical studies involving the use of MC in the most common pediatric tumors, with an overview of efficacy, toxicity, pharmacokinetic profile, and biomarkers. The best advantages of MC are low toxicity, oral administration and, thus, the feasibility of a more comfortable, home-based treatment, therefore improving the quality of life of the children themselves and of their parents and caregivers. Moreover, MC could represent a valid method to reduce the economic burden of anticancer therapy in the pediatric setting